PTEN and breast carcinoma: Consequently, PTEN-null breast cancer models show resistance to PI3Kα inhibitors but remain sensitive to pan-PI3K inhibitors [30], suggesting PTEN loss as a biomarker is more relevant for PI3Kα-specific inhibitors.